eli lilly and company zepbound - Search News

News

Eli Lilly's Share Price Sheds Some Weight

USA TODAY · 2h

Eli Lilly closer to breakthrough weight loss drug; shares tumble as some question results

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial saw people lose 12% of body weight.

CBS News on MSN · 19h

Eli Lilly weight loss pill shows promise in latest clinical trial, company says

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight loss options after a 72-week period.

Seeking Alpha · 20h

Eli Lilly's Share Price Sheds Some Weight: This Doesn't Mean To Pile In

Eli Lilly stock beats Q2 estimates with strong sales but faces competitive risks and high valuation. Here's why investors may simply want to hold for now.

6h

Eli Lilly: 50% Upside For LLY Stock?

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

1d

Eli Lilly is giving Novo Nordisk a run for its money—so why is LLY stock still down today?

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

7hon MSN

Eli Lilly and Company (NYSE:LLY) Q2 2025 Earnings Call Transcript

Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q2 2025 Earnings Conference Call. [Operator ...

23h

Eli Lilly second quarter earnings beat on strong GLP-1 sales, but stock dives on GLP-1 pill trial results

Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...

2d

Eli Lilly Q2 Preview: Can Mounjaro and Zepbound Keep Delivering?

Eli Lilly & Co. reports Q2 2025 results before the U.S. market opens on August 7. Analysts expect revenue of approximately ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results